|
KMID : 0351619780190010065
|
|
Kyungpook Medical Journal
1978 Volume.19 No. 1 p.65 ~ p.70
|
|
|
Antitumor Effect of 1, 3-bis(2-chloroethy1)-1-Nitrosourea with Tubercin-3 on Ehrlich Ascites Carcinoma in Mice
|
|
|
|
|
Abstract
|
|
|
1.3-bis(2-chioroethyl)-1-nitrosourea, BCNU, was synthetized by Schable et ai. , at National Cancer Chemot!ierapy Research Institute in 1963 and numerous experimental works carried out to determine the optimal dosage of BCNU for various types of human and animal cancer. Due to rarro--nes~ bet~,veen tumor effective -close and toxic dose, there appeared a variety of do BCNU to be used in cancer.
It svgs an annoying problem that the seemingly optimal dose in one patient would sometimes induce serious side effects.
This study ,vas carried out to determine the efficacy of lower dose of BCNU with immunotherapeutic agent tubercin-3, tuberculoprotein complex, extracted from human type mycobacterium tuberculosis in Ehlich excited mice. Sixty tumor-bearing mice were divided into 6 groups; 10 animals in each group receiving saline, tubercin-3, 2mg or 4mg per kg body weight of BCNU, and 2ntg, Medicine 4mg per kg body weight of BCNU combined with tubercin-3, respectively in each time.. Treatment was started 24 hours after tumor cell implantation and every other day for six times. The tubercin-3 was administered subcutaneously and BCNU intraperitoneally.
After treatment began, the animal condition was observed daily two times and the time of death was recorded for life expectation of mice. The Average increases of animal life span of each group were respectively as follows. Control is 13.8 days; tubercin-3 administration, 27.8 days; 2mg per kg body weight BCNU, 36.4 days; 4mg per kg body weight 1:3CNU, 38.6 days; 2mg BCNU with tubercin-3, 42.6 days; and 4mg BCNU with tubercin-3, 43.5 days.
Conclusively, the therapeutic potentiation is reflected to be f~xtended life span in combined treatment of tubercin-3 and BCNU then none combined and it was also noticed that the low dose of .BCNU could extend the life of Ehrlich ascites cancer-bearing; mice when administered in combination with tubercin-3.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|